5817-96-9: 5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one impurity

It is one of impurity present in Tofacitinib, Tofacitinib is an inhibitor of Janus kinases is a group of intracellular enzymes involved in signaling pathways that affect hematopoiesis and immune cell function, prevent the body from responding to cytokine signals. Tofacitinib is a partial and reversible Janus kinase inhibitor that prevents the body from responding to cytokine signals. which use is associated with a rapid decrease in C-reactive protein dose-dependent decreases in natural killer cells, and dose-dependent increases in B cells.

Additional information on CAS 5817-96-9

Catalogue No.

VE0010061

CAS No.

5817-96-9

Molecular Formula

C6H5N3O

Molecular Weight

135.12 g/mol

Parent drug

Tofacitinib

IUPAC Name

5, 7-dihydro-6H-pyrrolo [2, 3-d] pyrimidin-6-one

Synonyms

N/A

References

Cada, D. J., Demaris, K., Levien, T. L., & Baker, D. E. (2013). Tofacitinib. Hospital Pharmacy, 48(5), 413–424. https://doi.org/10.1310/hpj4805-413

Status

In-stock

[rfq_list]

Login first to add product to RFQ List

Request a quote

5817-96-9: 5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one impurity

5817-96-9: 5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one impurity
Catalogue No.

VE0010061

CAS No.

5817-96-9

Molecular Formula

C6H5N3O

Molecular Weight

135.12 g/mol

Parent drug

Tofacitinib

IUPAC Name

5, 7-dihydro-6H-pyrrolo [2, 3-d] pyrimidin-6-one

Synonyms

N/A

References

Cada, D. J., Demaris, K., Levien, T. L., & Baker, D. E. (2013). Tofacitinib. Hospital Pharmacy, 48(5), 413–424. https://doi.org/10.1310/hpj4805-413

Status

In-stock

ListName

5, 7-dihydro-6H-pyrrolo [2, 3-d] pyrimidin-6-one impurity

Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden